russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2022-5195russjcardiol-5195Research ArticleСОВЕТ ЭКСПЕРТОВEXPERT CONSENSUSВоздействие на автономную регуляцию сердечно-сосудистой системы как стратегическое направление лечения артериальной гипертензии, нарушений ритма и сердечной недостаточностиInfluence on the autonomic cardiovascular system regulation in the treatment of hypertension, arrhythmias and heart failurehttps://orcid.org/0000-0003-2929-0980ШляхтоЕ. В.ShlyakhtoE. V.

Доктор медицинских наук, профессор, академик РАН, генеральный директор, Президент Российского кардиологического общества, Заслуженный деятель науки РФ, главный кардиолог Санкт-Петербурга и Северо-Западного федерального округа

Санкт-Петербург

St. Petersburg

zvartau_ne@almazovcentre.ruhttps://orcid.org/0000-0001-8169-7812КонрадиА. О.KonradiA. O.

Доктор медицинских наук, профессор, заведующая кафедрой кардиологии, начальник службы анализа и перспективного планирования

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0001-6533-5950ЗвартауН. Э.ZvartauN. E.

Кандидат медицинских наук, старший научный сотрудник НИЛ патогенеза и терапии артериальной гипертензии, заместитель генерального директора по работе с регионами, начальник управления по реализации федеральных проектов, доцент кафедры внутренних болезней Института медицинского образования

Санкт-Петербург

St. Petersburg

zvartau_ne@almazovcentre.ruhttps://orcid.org/0000-0001-5981-1754НедогодаС. В.NedogodaS. V.

Заведующая кафедрой терапии и эндокринологии факультета усовершенствования врачей

Волгоград

Volgograd

https://orcid.org/0000-0003-1943-1137ЛопатинЮ. М.LopatinYu. M.

Доктор медицинских наук, профессор, заведующая кафедрой кардиологии, сердечно-соcудистой и торакальной хирургии Института НМФО, заведующая кардиологическим отделением

Волгоград

Volgograd

https://orcid.org/0000-0002-0139-5177СитниковаМ. Ю.SitnikovaM. Yu.

Доктор медицинских наук, профессор, руководитель научно-исследовательского отдела сердечной недостаточности, ведущий научный сотрудник лаборатории высокотехнологичных методов лечения сердечной недостаточности, профессор кафедры внутренних болезней Института медицинского образования

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-6553-9141МихайловЕ. Н.MikhailovE. N.

Доктор медицинских наук, заместитель директора Института сердца и сосудов по научной работе, руководитель НИЛ нейромодуляции, профессор кафедры сердечно-сосудистой хирургии Института медицинского образования

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-8788-0076БарановаЕ. И.BaranovaE. I.

Доктор медицинских наук, профессор кафедры терапии факультетской с курсом кардиологии, эндокринологии и функциональной диагностики с клиникой, директор НИИ сердечно-сосудистых заболеваний научно-клинического исследовательского центра

Санкт-Петербург

St. Petersburg

https://orcid.org/0000-0002-4510-6197ГалявичА. С.GalyavichA. S.

Доктор медицинских наук, профессор, вице-президент Российского кардиологического общества, заведующая кафедрой кардиологии

Казань

Kazan

https://orcid.org/0000-0002-6453-2976ДупляковД. В.DuplyakovD. V.

Доктор медицинских наук, профессор, заместитель главного врача по медицинской части

Самара

Samara

https://orcid.org/0000-0002-6611-9165СаласюкА. С.SalasyukA. S.

Кандидат медицинских наук, доцент кафедры внутренних болезней

Волгоград

Volgograd

https://orcid.org/0000-0001-5129-9944ГалагудзаМ. М.GalagudzaM. M.

Доктор медицинских наук, профессор, член-корр. РАН, директор Института экспериментальной медицины, главный научный сотрудник НИО микроциркуляции и метаболизма миокарда, заведующий кафедрой патологии Института медицинского образования

Санкт-Петербург

St. Petersburg

ФГБУ Национальный медицинский исследовательский центр им. В.А. Алмазова Минздрава РоссииРоссияAlmazov National Medical Research CenterRussian FederationФГБОУ ВО Волгоградский государственный медицинский университет Минздрава РоссииРоссияVolgograd State Medical UniversityRussian FederationФГБОУ ВО Волгоградский государственный медицинский университет Минздрава России; ГБУЗ Волгоградский областной клинический кардиологическийРоссияVolgograd State Medical University; Volgograd Regional Clinical Cardiology CenterRussian FederationФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова Минздрава РоссииРоссияPavlov First State Medical UniversityRussian FederationФГБОУ ВО Казанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationГБУЗ Самарский областной клинический кардиологический диспансерРоссияSamara Regional Clinical Cardiology DispensaryRussian Federation20222508202227951955195Copyright © Шляхто Е.В., Конради А.О., Звартау Н.Э., Недогода С.В., Лопатин Ю.М., Ситникова М.Ю., Михайлов Е.Н., Баранова Е.И., Галявич А.С., Дупляков Д.В., Саласюк А.С., Галагудза М.М., 20222022Шляхто Е.В., Конради А.О., Звартау Н.Э., Недогода С.В., Лопатин Ю.М., Ситникова М.Ю., Михайлов Е.Н., Баранова Е.И., Галявич А.С., Дупляков Д.В., Саласюк А.С., Галагудза М.М.Shlyakhto E.V., Konradi A.O., Zvartau N.E., Nedogoda S.V., Lopatin Y.M., Sitnikova M.Y., Mikhailov E.N., Baranova E.I., Galyavich A.S., Duplyakov D.V., Salasyuk A.S., Galagudza M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5195

Сердечно-сосудистые заболевания широко распространены и являются ведущей причиной смертности населения в большинстве стран мира, несмотря на создание и совершенствование стратегий снижения сердечно-сосудистого риска. Существенная роль в развитии и эволюции сердечно-сосудистых заболеваний принадлежит повышенной активности симпатической нервной системы, поэтому методы воздействия на нее являются актуальными для профилактики и терапии кардиоваскулярной патологии. В статье рассмотрены современные подходы к интервенционной и медикаментозной регуляции автономной нервной системы и нейромодуляции в профилактике и лечении артериальной гипертензии, хронической сердечной недостаточности, тахиаритмий, и отражено консолидированное экспертное мнение по данным вопросам.

Cardiovascular diseases are widespread and are the leading death cause in most countries, despite the creation and improvement of strategies to reduce cardiovascular risk. A significant role in the development and evolution of cardiovascular diseases belongs to sympathetic nervous system hyperactivity, and therefore the methods of effecting it are relevant for the prevention and treatment of cardiovascular pathology. The article discusses modern approaches to interventional and conservative regulation of the autonomic nervous system and neuromodulation in the prevention and treatment of hypertension, heart failure, tachyarrhythmias, as well as reflects a conjoint expert judgment on these issues.

нейромодуляцияартериальная гипертензияхроническая сердечная недостаточностьтахиаритмииneuromodulationhypertensionheart failuretachyarrhythmiasReferencesWHO. The top 10 causes of death [Electronic resource]. URL: https://www.who.int/newsroom/fact-sheets/detail/the-top-10-causes-of-death (accessed: 23.08.2021).WHO. The top 10 causes of death [Electronic resource]. URL: https://www.who.int/newsroom/fact-sheets/detail/the-top-10-causes-of-death (accessed: 23.08.2021).Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37.Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37.Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure: 0. AME Medical Journal. AME Publishing Company. 2020;5(0).Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure: 0. AME Medical Journal. AME Publishing Company. 2020;5(0).Foëx P, Sear J. Hypertension: pathophysiology and treatment. Continuing Education in Anaesthesia Critical Care & Pain. 2004;4(3):71-5.Foëx P, Sear J. Hypertension: pathophysiology and treatment. Continuing Education in Anaesthesia Critical Care & Pain. 2004;4(3):71-5.Beevers G, Lip GYH, O’Brien E. The pathophysiology of hypertension. BMJ. 2001;322(7291):912-6.Beevers G, Lip GYH, O’Brien E. The pathophysiology of hypertension. BMJ. 2001;322(7291):912-6.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21(5):365-71.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21(5):365-71.Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989;2(3) Pt 2:140S-146S.Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989;2(3) Pt 2:140S-146S.Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clinical Science. 1993;84(2):225-30.Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clinical Science. 1993;84(2):225-30.Конради А.О. Взаимодействие между симпатической нервной системой и ренин-ангиотензиновой системой. Роль в повышении артериального давления. Артериальная гипертензия. 2012;18(6):577-83. doi:10.18705/1607-419X-2012-18-6-577-583.Konradi AO. Interaction between the sympathetic nervous system and the reninangiotensin system. The role in increasing blood pressure. Arterial hypertension. 2012;18(6):577-83. (In Russ.) doi:10.18705/1607-419X-2012-18-6-577-583.Шляхто Е.В., Конради А.О. Причины и последствия активации симпатической нервной системы при артериальной гипертензии. Артериальная гипертензия. 2003;9(3):81-8. doi:10.18705/1607-419X-2003-9-3-81-88.Shlyakhto EV, Konradi AO. Causes and consequences of activation of the sympathetic nervous system in arterial hypertension. Arterial hypertension. 2003;9(3):81-8. (In Russ.) doi:10.18705/1607-419X-2003-9-3-81-88.Конради А.О. Ожирение, симпатическая гиперактивность и артериальная гипертензия — есть ли связь? Артериальная гипертензия. 2006;12(2):131-40. doi:10.18705/1607-419X-2006-12-2-131-140.Konradi AO. Obesity, sympathetic hyperactivity and arterial hypertension — is there a connection? Arterial hypertension. 2006;12(2):131-40. (In Russ.) doi:10.18705/1607-419X-2006-12-2-131-140.Johnson AK, Xue B. Central nervous system neuroplasticity and the sensitization of hypertension. Nat Rev Nephrol. 2018;14(12):750-66.Johnson AK, Xue B. Central nervous system neuroplasticity and the sensitization of hypertension. Nat Rev Nephrol. 2018;14(12):750-66.Marrelli M, Gentile S, Palmieri F, et al. Correlation between Surgeon’s experience, surgery complexity and the alteration of stress related physiological parameters. PLoS One. 2014;9(11):e112444. doi:10.1371/journal.pone.0112444.Marrelli M, Gentile S, Palmieri F, et al. Correlation between Surgeon’s experience, surgery complexity and the alteration of stress related physiological parameters. PLoS One. 2014;9(11):e112444. doi:10.1371/journal.pone.0112444.Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ. 2014;38(1):20-4.Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ. 2014;38(1):20-4.Harrison DG. The immune system in hypertension. Trans Am Clin Climatol Assoc. 2014;125:130-8; discussion 138-40.Harrison DG. The immune system in hypertension. Trans Am Clin Climatol Assoc. 2014;125:130-8; discussion 138-40.Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the Immune System in Hypertension. Physiol Rev. 2017;97(3):1127-64.Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the Immune System in Hypertension. Physiol Rev. 2017;97(3):1127-64.Conde SV, Ribeiro MJ, Melo BF, et al. Insulin resistance: a new consequence of altered carotid body chemoreflex? J Physiol. 2017;595(1):31-41. doi:10.1113/JP271684.Conde SV, Ribeiro MJ, Melo BF, et al. Insulin resistance: a new consequence of altered carotid body chemoreflex? J Physiol. 2017;595(1):31-41. doi:10.1113/JP271684.Paton JFR. Targeting autonomic imbalance in pathophysiology: is the carotid body the new nirvana? J Physiol. 2017;595(1):29-30.Paton JFR. Targeting autonomic imbalance in pathophysiology: is the carotid body the new nirvana? J Physiol. 2017;595(1):29-30.Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens. 1998;16(12):1979-87.Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens. 1998;16(12):1979-87.Wenzel RR, Spieker L, Qui S, et al. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension. 1998;32(6):1022-7. doi:10.1161/01.hyp.32.6.1022.Wenzel RR, Spieker L, Qui S, et al. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension. 1998;32(6):1022-7. doi:10.1161/01.hyp.32.6.1022.Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60(5):621-9.Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60(5):621-9.Almazov VA, Shlyakhto EV, Blagosklonnaya YV, et al. Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy. Journal of Hypertension. 2000;18:S12.Almazov VA, Shlyakhto EV, Blagosklonnaya YV, et al. Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy. Journal of Hypertension. 2000;18:S12.Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006;8(4):456-65. doi:10.1111/j.1463-1326.2006.00606.x.Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006;8(4):456-65. doi:10.1111/j.1463-1326.2006.00606.x.Чубенко Е.А., Беляева О. Д., Баженова Т.Л. и др. Плейотропные эффекты моксонидина. Артериальная гипертензия. 2010;16(4):351-5.Chubenko EA, Belyaeva OD, Bazhenova TL, et al. Pleiotropic effects of moxonidine. Arterial hypertension. 2010;16(4):351-5. (In Russ.)Демидова Т.Ю., Аметов А.С., Смагина Л.В. Моксонидин в коррекции метаболических нарушений и эндотелиальной дисфункции у больных сахарным диабетом типа 2, ассоциированным с артериальной гипертензией. Артериальная гипертензия. 2004;10(2):104-9. doi:10.18705/1607-419X-2004-10-2-104-109.Demidova TYu, Ametov AS, Smagina LV. Moxonidine in the correction of metabolic disorders and endothelial dysfunction in patients with type 2 diabetes mellitus associated with arterial hypertension. Arterial hypertension. 2004;10(2):104-9. (In Russ.) doi:10.18705/1607-419X-2004-10-2-104-109.Скибицкий В.В., Гутова С.Р., Фендрикова А.В. и др. Антигипертензивная, вазопротективная и метаболическая эффективность комбинированной фармакотерапии у больных артериальной гипертонией с предиабетом. Кардиология и сердечно-сосудистая хирургия. 2021;14(6):490-8. doi:10.17116/kardio202114061490.Skibitsky VV, Gutova SR, Fendrikova AV, et al. Antihypertensive, vasoprotective and metabolic efficacy of combined pharmacotherapy in hypertensive patients with prediabetes. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2021;14(6):4908. (In Russ.) doi:10.17116/kardio202114061490.Недогода С.В., Чумачек Е.В., Ледяева А.А. и др. Возможности нефиксированной комбинации периндоприл + моксонидин в достижении целевого АД при артериальной гипертензии и метаболическом синдроме. Кардиология и сердечнососудистая хирургия. 2021;14(2):20814.Nedogoda SV, Chumachek EV, Ledyaeva AA, et al. Non-fixed combination perindopril+moxonidine for blood pressure control in hypertensive patients with metabolic syndrome. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2021;14(2):20814. (In Russ.)Недогода С.В., Чумачек Е.В., Ледяева А.А. и др. Возможности ангиопротекции при артериальной гипертензии и метаболическом синдроме на терапии нефиксированной комбинацией периндоприл + моксонидин. Кардиология и сердечно-сосудистая хирургия. 2021;14(6):499-504. doi:10.17116/kardio202114061499.Nedogoda SV, Chumachenko EV, Ledyaeva AA, et al. The possibilities of angioprotection in arterial hypertension and metabolic syndrome on therapy with a fixed combination of perindopril + moxonidine. Cardiology and cardiovascular surgery. 2021;14(6):499-504. (In Russ.) doi:10.17116/kardio202114061499.Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351-8. doi:10.1093/eurheartj/ehq205.Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351-8. doi:10.1093/eurheartj/ehq205.Dudinskaya E, Tkacheva O, Bazaeva E, et al. Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07235-6. Epub ahead of print.Dudinskaya E, Tkacheva O, Bazaeva E, et al. Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07235-6. Epub ahead of print.Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18(9):669-75.Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18(9):669-75.Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.Schlaich MP, Almahmeed W, Arnaout S, et al. The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT). Curr Med Res Opin. 2020;36(12):1939-45. doi:10.1080/03007995.2020.1835852.Schlaich MP, Almahmeed W, Arnaout S, et al. The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT). Curr Med Res Opin. 2020;36(12):1939-45. doi:10.1080/03007995.2020.1835852.Конради А.О., Звартау Н.Э., Чазова И.Е. и др. Особенности антигипертензивной терапии и практика назначения селективных агонистов имидазолиновых рецепторов в России по сравнению с другими странами: анализ данных исследования STRAIGHT. Терапевтический архив. 2021;93(4):440-8. doi:10.26442/00403660.2021.04.200818.Konradi AO, Zvartau NE, Chazova IE, et al. Features of antihypertensive therapy and realworld prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. Terapevticheskii arkhiv. 2021;93(4):440-8. (In Russ.) doi:10.26442/00403660.2021.04.200818.Carnagarin R, Matthews V, Gregory C, Schlaich MP. Pharmacotherapeutic strategies for treating hypertension in patients with obesity. Expert Opin Pharmacother. 2018;19(7):643- 51. doi:10.1080/14656566.2018.1458092.Carnagarin R, Matthews V, Gregory C, Schlaich MP. Pharmacotherapeutic strategies for treating hypertension in patients with obesity. Expert Opin Pharmacother. 2018;19(7):643- 51. doi:10.1080/14656566.2018.1458092.Suvarna VR. Real world evidence (RWE) — Are we (RWE) ready? Perspect Clin Res. 2018;9(2):61-3.Suvarna VR. Real world evidence (RWE) — Are we (RWE) ready? Perspect Clin Res. 2018;9(2):61-3.Ali A, Kanth AV, Mohanty R, et al. Real World Evidence: An Overview of its Importance in the Current Scenario. International Journal of Pharmaceutical Sciences Review and Research. 2016;39:251-4.Ali A, Kanth AV, Mohanty R, et al. Real World Evidence: An Overview of its Importance in the Current Scenario. International Journal of Pharmaceutical Sciences Review and Research. 2016;39:251-4.Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-27.Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-27.Kiuchi MG, Ganesan K, Keating J, et al. Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model. Clin Res Cardiol. 2021;110:740-53. doi:10.1007/s00392-021-01814-1.Kiuchi MG, Ganesan K, Keating J, et al. Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model. Clin Res Cardiol. 2021;110:740-53. doi:10.1007/s00392-021-01814-1.Gierthmuehlen M, Plachta DTT, Zentner J. Implant-Mediated Therapy of Arterial Hypertension. Curr Hypertens Rep. 2020;22(2):16. doi:10.1007/s11906-020-1019-7.Gierthmuehlen M, Plachta DTT, Zentner J. Implant-Mediated Therapy of Arterial Hypertension. Curr Hypertens Rep. 2020;22(2):16. doi:10.1007/s11906-020-1019-7.Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41(2):233-43.Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41(2):233-43.Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615-21. doi:10.1161/01.cir.73.4.615.Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615-21. doi:10.1161/01.cir.73.4.615.Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and betaadrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307(4):205-11. doi:10.1056/NEJM198207223070401.Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and betaadrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307(4):205-11. doi:10.1056/NEJM198207223070401.Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058-66.Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058-66.Badrov MB, Mak S, Floras JS. Cardiovascular Autonomic Disturbances in Heart Failure With Preserved Ejection Fraction. Can J Cardiol. 2021;37(4):609-20.Badrov MB, Mak S, Floras JS. Cardiovascular Autonomic Disturbances in Heart Failure With Preserved Ejection Fraction. Can J Cardiol. 2021;37(4):609-20.Stabile AM, Aceros H, Stockmeyer K, et al. Functional and molecular effects of imidazoline receptor activation in heart failure. Life Sci. 2011;88(11-12):493-503. doi:10.1016/j.lfs.2011.01.008.Stabile AM, Aceros H, Stockmeyer K, et al. Functional and molecular effects of imidazoline receptor activation in heart failure. Life Sci. 2011;88(11-12):493-503. doi:10.1016/j.lfs.2011.01.008.Honda N, Hirooka Y, Ito K, et al. Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. J Hypertens. 2013;31(11):2300-8; discussion 2308. doi:10.1097/HJH.0b013e328364a2a1.Honda N, Hirooka Y, Ito K, et al. Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. J Hypertens. 2013;31(11):2300-8; discussion 2308. doi:10.1097/HJH.0b013e328364a2a1.Cohn JN, Pfeffer MA, Rouleau J, et al.; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659-67. doi:10.1016/s1388-9842(03)00163-6.Cohn JN, Pfeffer MA, Rouleau J, et al.; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659-67. doi:10.1016/s1388-9842(03)00163-6.Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412. doi:10.1002/ejhf.1741.Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412. doi:10.1002/ejhf.1741.Cohen JB, Schrauben SJ, Zhao L, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8(3):172-84. doi:10.1016/j.jchf.2019.09.009.Cohen JB, Schrauben SJ, Zhao L, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8(3):172-84. doi:10.1016/j.jchf.2019.09.009.Tse HF, Turner S, Sanders P, et al. Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART study): first-in-man experience. Heart Rhythm. 2015;12(3):588-95. doi:10.1016/j.hrthm.2014.12.014.Tse HF, Turner S, Sanders P, et al. Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART study): first-in-man experience. Heart Rhythm. 2015;12(3):588-95. doi:10.1016/j.hrthm.2014.12.014.Zipes DP, Neuzil P, Theres H, et al. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC Heart Fail. 2016;4(2):129-36. doi:10.1016/j.jchf.2015.10.006.Zipes DP, Neuzil P, Theres H, et al. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC Heart Fail. 2016;4(2):129-36. doi:10.1016/j.jchf.2015.10.006.Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015;36(7):425-33. doi:10.1093/eurheartj/ehu345.Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015;36(7):425-33. doi:10.1093/eurheartj/ehu345.Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016;68(2):149-58. doi:10.1016/j.jacc.2016.03.525.Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016;68(2):149-58. doi:10.1016/j.jacc.2016.03.525.Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015;3(6):487-96. doi:10.1016/j.jchf.2015.02.006.Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015;3(6):487-96. doi:10.1016/j.jchf.2015.02.006.Patel HC, Rosen SD, Hayward C, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016;18(6):703- 12. doi:10.1002/ejhf.502.Patel HC, Rosen SD, Hayward C, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016;18(6):703- 12. doi:10.1002/ejhf.502.Murray A, Mahadi M, Deuchars S, et al. The strange case of the ear and the heart: The auricular vagus nerve and its influence on cardiac control. Autonomic Neuroscience. 2016;199:48-53. doi:10.1016/j.autneu.2016.06.004.Murray A, Mahadi M, Deuchars S, et al. The strange case of the ear and the heart: The auricular vagus nerve and its influence on cardiac control. Autonomic Neuroscience. 2016;199:48-53. doi:10.1016/j.autneu.2016.06.004.Afanasiev SA, Pavliukova EN, Kuzmichkina MA. Nonpharmacological Correction of Hypersympatheticotonia in Patients with Chronic Coronary Insufficiency and Severe Left Ventricular Dysfunction. Ann Noninvasive Electrocardiol. 2016;21(6):548-56. doi:10.1111/anec.12349.Afanasiev SA, Pavliukova EN, Kuzmichkina MA. Nonpharmacological Correction of Hypersympatheticotonia in Patients with Chronic Coronary Insufficiency and Severe Left Ventricular Dysfunction. Ann Noninvasive Electrocardiol. 2016;21(6):548-56. doi:10.1111/anec.12349.Fudim M, Jones WS, Boortz-Marx RL, et al. Splanchnic Nerve Block for Acute Heart Failure. Circulation. 2018;138(9):951-3. doi:10.1161/CIRCULATIONAHA.118.035260.Fudim M, Jones WS, Boortz-Marx RL, et al. Splanchnic Nerve Block for Acute Heart Failure. Circulation. 2018;138(9):951-3. doi:10.1161/CIRCULATIONAHA.118.035260.Fudim M, Boortz-Marx RL, Ganesh A, et al. Splanchnic Nerve Block for Chronic Heart Failure. JACC Heart Fail. 2020;8(9):742-52. doi:10.1016/j.jchf.2020.04.010.Fudim M, Boortz-Marx RL, Ganesh A, et al. Splanchnic Nerve Block for Chronic Heart Failure. JACC Heart Fail. 2020;8(9):742-52. doi:10.1016/j.jchf.2020.04.010.Mikhaylov EN, Moshonkina TR, Zharova EN, et al. Acute Cardiovascular Effects of NonInvasive Electrical Spinal Cord Stimulation: Results from a Pilot Study in Humans. J. of Cardiovasc. Trans. Res. 2020;13:891-3. doi:10.1007/s12265-020-10014-7.Mikhaylov EN, Moshonkina TR, Zharova EN, et al. Acute Cardiovascular Effects of NonInvasive Electrical Spinal Cord Stimulation: Results from a Pilot Study in Humans. J. of Cardiovasc. Trans. Res. 2020;13:891-3. doi:10.1007/s12265-020-10014-7.Deftereos S, Giannopoulos G, Kossyvakis C, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol. 2013;112(5):684-7. doi:10.1016/j.amjcard.2013.04.049.Deftereos S, Giannopoulos G, Kossyvakis C, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol. 2013;112(5):684-7. doi:10.1016/j.amjcard.2013.04.049.Giannopoulos G, Kossyvakis C, Efremidis M, et al. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. Circulation. 2014;130(16):1346-52. doi:10.1161/CIRCULATIONAHA.114.010999.Giannopoulos G, Kossyvakis C, Efremidis M, et al. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. Circulation. 2014;130(16):1346-52. doi:10.1161/CIRCULATIONAHA.114.010999.Stavrakis S, Po S. Ganglionated Plexi Ablation: Physiology and Clinical Applications. Arrhythm Electrophysiol Rev. 2017;6(4):186-90. doi:10.15420/aer2017.26.1.Stavrakis S, Po S. Ganglionated Plexi Ablation: Physiology and Clinical Applications. Arrhythm Electrophysiol Rev. 2017;6(4):186-90. doi:10.15420/aer2017.26.1.Lemery R, Birnie D, Tang ASL, et al. Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. Heart Rhythm. 2006;3(4):387-96. doi:10.1016/j.hrthm.2006.01.009.Lemery R, Birnie D, Tang ASL, et al. Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation. Heart Rhythm. 2006;3(4):387-96. doi:10.1016/j.hrthm.2006.01.009.Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013;62(24):2318-25. doi:10.1016/j.jacc.2013.06.053.Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013;62(24):2318-25. doi:10.1016/j.jacc.2013.06.053.Mikhaylov E, Kanidieva A, Sviridova N, et al. Outcome of anatomic ganglionated plexi ablation to treat paroxysmal atrial fibrillation: a 3-year follow-up study. Europace. 2011;13(3):362-70. doi:10.1093/europace/euq416.Mikhaylov E, Kanidieva A, Sviridova N, et al. Outcome of anatomic ganglionated plexi ablation to treat paroxysmal atrial fibrillation: a 3-year follow-up study. Europace. 2011;13(3):362-70. doi:10.1093/europace/euq416.Mujer MT, Abcha AA, Saleh Y, et al. Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta-analysis. Pacing Clin Electrophysiol. 2020;43(8):866-74. doi:10.1111/pace.14009.Mujer MT, Abcha AA, Saleh Y, et al. Effect of combined renal denervation and pulmonary vein isolation in atrial fibrillation recurrence in hypertensive patients: A meta-analysis. Pacing Clin Electrophysiol. 2020;43(8):866-74. doi:10.1111/pace.14009.Turagam MK, Whang W, Miller MA, et al. Renal Sympathetic Denervation as Upstream Therapy During Atrial Fibrillation Ablation: Pilot HFIB Studies and Meta-Analysis. JACC Clin Electrophysiol. 2021;7(1):109-23. doi:10.1016/j.jacep.2020.08.013.Turagam MK, Whang W, Miller MA, et al. Renal Sympathetic Denervation as Upstream Therapy During Atrial Fibrillation Ablation: Pilot HFIB Studies and Meta-Analysis. JACC Clin Electrophysiol. 2021;7(1):109-23. doi:10.1016/j.jacep.2020.08.013.Stavrakis S, Humphrey MB, Scherlag BJ, et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J Am Coll Cardiol. 2015;65(9):867-75. doi:10.1016/j.jacc.2014.12.026.Stavrakis S, Humphrey MB, Scherlag BJ, et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J Am Coll Cardiol. 2015;65(9):867-75. doi:10.1016/j.jacc.2014.12.026.Stavrakis S, Stoner JA, Humphrey MB, et al. TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial. JACC Clin Electrophysiol. 2020;6(3):282-91. doi:10.1016/j.jacep.2019.11.008.Stavrakis S, Stoner JA, Humphrey MB, et al. TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial. JACC Clin Electrophysiol. 2020;6(3):282-91. doi:10.1016/j.jacep.2019.11.008.Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ehv316.Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ehv316.Raskin JS, Liu JJ, Abrao A, et al. Minimally invasive posterior extrapleural thoracic sympathectomy in children with medically refractory arrhythmias. Heart Rhythm. 2016;13(7):1381-5. doi:10.1016/j.hrthm.2016.03.041.Raskin JS, Liu JJ, Abrao A, et al. Minimally invasive posterior extrapleural thoracic sympathectomy in children with medically refractory arrhythmias. Heart Rhythm. 2016;13(7):1381-5. doi:10.1016/j.hrthm.2016.03.041.Vander MA, Fedotov PA, Lyubimtseva TA, et al. Renal artery denervation suppresses intractable ventricular arrhythmia in patients with left heart thrombosis. J Geriatr Cardiol. 2017;14(9):587-9. doi:10.11909/j.issn.1671-5411.2017.09.005.Vander MA, Fedotov PA, Lyubimtseva TA, et al. Renal artery denervation suppresses intractable ventricular arrhythmia in patients with left heart thrombosis. J Geriatr Cardiol. 2017;14(9):587-9. doi:10.11909/j.issn.1671-5411.2017.09.005.

The authors declare that there are no conflicts of interest present.